Bayer Challenges J&J OTC Leadership With Buy Of China's Dihon Pharma
This article was originally published in PharmAsia News
Executive Summary
Bayer plans to buy Dihon Pharmaceutical Group, a China-based maker of traditional Chinese medicine, in a push to challenge Johnson & Johnson's leadership in the global over-the-counter market.